TY - JOUR
T1 - Low adherence to antidepressants is associated with increased mortality following stroke
T2 - A large nationally representative cohort study
AU - Krivoy, Amir
AU - Stubbs, Brendon
AU - Balicer, Ran D.
AU - Weizman, Shira
AU - Feldman, Becca
AU - Hoshen, Moshe
AU - Zalsman, Gil
AU - Hochman, Eldar
AU - Shoval, Gal
N1 - Publisher Copyright:
© 2017 Elsevier B.V. and ECNP
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Post stroke depression is common and pervasive. In the general population, there has been some controversy that antidepressant (AD) medication is associated with premature mortality. Data is still lacking regarding the association between adherence to antidepressants (AD) and all-cause mortality. In this retrospective analysis of a population-based cohort of patients, 32,361 post-stroke patients who purchased at least one AD were followed for all-cause mortality over 4-years. Adherence to AD was measured as a ratio between dispensed and prescribed durations and was modeled as: non-adherence (<20%, n=8619), poor (20–50%, n=5108), moderate (50–80%, n=5656), and good (>80%, n=12,978) adherence. Multivariable survival analyses, adjusted for demographic and clinical variables including physical comorbidities known to influence mortality, were conducted. Unadjusted mortality rates were 16.5%, 20.2%, 22.2% and 23.7% in those classified as non-adherent, poor, moderate and good adherence respectively (χ2=174.6, p<0.0001). In the adjusted model, the non-adherent and poor adherence groups had significantly increased mortality Hazard Ratios (HR) of 1.25 (95% CI: 1.17–1.33) and 1.17 (95% CI: 1.09–1.26) respectively compared to the good adherence group. This nationally representative data suggests that poor adherence to AD is associated with increased all-cause mortality among people who had a stroke. Given our findings and the high prevalence of anxiety and depression along with AD effectiveness, efforts to promote AD adherence in this population may be warranted in clinical practice.
AB - Post stroke depression is common and pervasive. In the general population, there has been some controversy that antidepressant (AD) medication is associated with premature mortality. Data is still lacking regarding the association between adherence to antidepressants (AD) and all-cause mortality. In this retrospective analysis of a population-based cohort of patients, 32,361 post-stroke patients who purchased at least one AD were followed for all-cause mortality over 4-years. Adherence to AD was measured as a ratio between dispensed and prescribed durations and was modeled as: non-adherence (<20%, n=8619), poor (20–50%, n=5108), moderate (50–80%, n=5656), and good (>80%, n=12,978) adherence. Multivariable survival analyses, adjusted for demographic and clinical variables including physical comorbidities known to influence mortality, were conducted. Unadjusted mortality rates were 16.5%, 20.2%, 22.2% and 23.7% in those classified as non-adherent, poor, moderate and good adherence respectively (χ2=174.6, p<0.0001). In the adjusted model, the non-adherent and poor adherence groups had significantly increased mortality Hazard Ratios (HR) of 1.25 (95% CI: 1.17–1.33) and 1.17 (95% CI: 1.09–1.26) respectively compared to the good adherence group. This nationally representative data suggests that poor adherence to AD is associated with increased all-cause mortality among people who had a stroke. Given our findings and the high prevalence of anxiety and depression along with AD effectiveness, efforts to promote AD adherence in this population may be warranted in clinical practice.
KW - Adherence
KW - Antidepressants
KW - Anxiety
KW - CVA
KW - Depression
KW - Mortality
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85028708447&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2017.08.428
DO - 10.1016/j.euroneuro.2017.08.428
M3 - Article
C2 - 28886897
AN - SCOPUS:85028708447
SN - 0924-977X
VL - 27
SP - 970
EP - 976
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 10
ER -